Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3927 in genetically confirmed propionic acidemia
NL-OMON60874Phase 2Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- May 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of mRNA-3927 in propionic acidemia (PA) (3 arms), sponsored by Moderna Inc. Primary endpoints: Safety and tolerability and Metabolic decompensation event frequency. Started May 2025; status: active, not recruiting.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on NL-OMON60874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60874.